---
title: "Pyr01 selectively kills HIV-1–infected macrophages by triggering premature viral protease"
id: "biorxiv-20-selective-elimination-of-hiv-1-infected-macrophages-by-targeted-activator-of"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-20-selective-elimination-of-hiv-1-infected-macrophages-by-targeted-activator-of"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1?rss=1"
published_at: "2026-11-13T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pyr01 selectively kills HIV-1–infected macrophages by triggering premature viral protease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-20-selective-elimination-of-hiv-1-infected-macrophages-by-targeted-activator-of
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1?rss=1)
- **Published At:** 2026-11-13T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Investigators tested non-nucleoside reverse transcriptase inhibitor-derived molecules called Targeted Activator of Cell Kill (TACK) in primary human monocyte-derived macrophages (MDMs). - The study evaluated two related compounds: **Pyr01**, an active TACK compound developed by Merck, and **Pyr02**, described as an inactive analog. - Data indicated **Pyr01** had minimal toxicity against uninfected MDMs but potently reduced viability of HIV-1–infected MDMs. - The authors reported an approximate EC50 of 0.36 μM for **Pyr01** against infected macrophages. - Treatment with **Pyr01** produced a rapid and sustained drop in extracellular, virion-associated HIV-1 RNA and a significant decrease in cell-associated viral RNA. - Immunofluorescence microscopy and live-cell imaging showed a marked loss of HIV-1–infected macrophages after **Pyr01** exposure, consistent with selective elimination of infected cells. - **Pyr02** exhibited minimal anti–HIV-1 activity in the macrophage assays. - The proposed mechanism is premature activation of the viral protease in infected cells, driving cell-intrinsic death; the source attributes this mechanism to the TACK class. - The report did not present in vivo, clinical, or detailed dosing and safety data beyond the in vitro macrophage experiments. - Authors suggested that targeting macrophage reservoirs could complement strategies directed at CD4+ T-cell reservoirs to broaden cellular reach in HIV cure research.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=z8ryMiu.JI8KWkLJaxovXmZ5vh02qVpihXSjgI2svH4-1794640616.8240104-1.2.1.1-Dh8xrRhMMi5nUzROt6Ul_tNDS_ZEJqrAgku7m3pear2coHVO4jHyoCFiA6FF7Cwh) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Selective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill [ View ORCID Profile](http://orcid.org/0009-0007-5567-831X)Beatriz M. Lahoz, [ View ORCID Profile](http://orcid.org/0009-0008-3859-9684)Anouk A.J. Hamers, [ View ORCID Profile](http://orcid.org/0000-0003-4810-0214)Thaissa Cordeiro, [ View ORCID Profile](http://orcid.org/0000-0001-9651-2999)Mario Stevenson doi: https://doi.org/10.64898/2026.11.11.765927 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Beatriz M. Lahoz 1 University of Miami Miller School of Medicine, United States of America (the); * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Beatriz%2BM.%2BLahoz%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Lahoz%20BM&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABeatriz%2BM.%2BLahoz%2B) * [ORCID record for Beatriz M. Lahoz](http://orcid.org/0009-0007-5567-831X "Open in new tab") Anouk A.J. Hamers 1 University of Miami Miller School of Medicine, United States of America (the); * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anouk%2BA.J.%2BHamers%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Hamers%20AA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AAnouk%2BA.J.%2BHamers%2B) * [ORCID record for Anouk A.J. Hamers](http://orcid.org/0009-0008-3859-9684 "Open in new tab") Thaissa Cordeiro 1 University of Miami Miller School of Medicine, United States of America (the); * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Thaissa%2BCordeiro%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Cordeiro%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AThaissa%2BCordeiro%2B) * [ORCID record for Thaissa Cordeiro](http://orcid.org/0000-0003-4810-0214 "Open in new tab") Mario Stevenson 2 University of Miami School of Medicine, United States of America (the) * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mario%2BStevenson%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Stevenson%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMario%2BStevenson%2B) * [ORCID record for Mario Stevenson](http://orcid.org/0000-0001-9651-2999 "Open in new tab") * For correspondence: mstevenson@med.miami.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5960179/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5960179/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5960179/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5960179/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract In the pursuit of an HIV cure, elimination of persistent HIV reservoirs requires strategies that promote immune-mediated or cytopathic clearance of infected cells. While many such approaches are being developed against infected CD4+ T cells, HIV-infected macrophages are comparatively resistant to cell death and to several killing mechanisms being explored for T-cell reservoirs, highlighting the need for strategies that specifically eliminate this reservoir. Targeted Activator of Cell Kill (TACK), developed by Merck Pharmaceuticals, are non-nucleoside reverse transcriptase inhibitor-derived molecules designed to selectively kill HIV-1-infected cells by inducing premature activation of the viral protease. Here, we evaluated the TACK compounds Pyr01 and it?s inactive analog Pyr02, in primary human monocyte-derived macrophages (MDMs). Pyr01 had minimal effects on uninfected MDM viability but potently targeted HIV-1-infected MDMs, with an EC?? of approximately 0.36 ?M. Pyr01 treatment produced a rapid and sustained reduction in extracellular virion-associated HIV-1 RNA and significantly decreased cell-associated viral RNA, whereas Pyr02 exhibited minimal activity. Immunofluorescence microscopy and live-cell imaging further demonstrated a marked loss of HIV-1-infected macrophages following Pyr01 treatment, consistent with selective elimination of infected cells. These findings identify Pyr01 as a specific mediator of HIV-infected macrophage death and establish premature viral protease activation as a strategy for overcoming the intrinsic resistance of macrophage reservoirs to clearance. Targeting this macrophage-specific barrier may complement approaches directed at CD4+ T-cell reservoirs and broaden the cellular reach of HIV cure strategies. Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.11.12.761594v1 "Dual cellular targeting of complement receptor 2 \(CR2/CD21\) synergistically suppresses autoreactive germinal center activity and autoimmunity in lupus")[Next ](https://www.biorxiv.org/content/10.64898/2026.11.07.765060v1 "Exploratory positional differences in observed CDRH2 lineage-state transitions following HIV-1 germline-targeting vaccination") Posted November 13, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.11.11.765927v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/11/13/2026.11.11.765927.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) Selective Elimination of HIV-1-Infected Macrophages by Targeted Activator of Cell Kill Beatriz M. Lahoz, Anouk A.J. Hamers, Thaissa Cordeiro, Mario Stevenson bioRxiv 2026.11.11.765927; doi: https://doi.org/10.64898/2026.11.11.765927 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765927v1%26text%3DSelective%2520Elimination%2520of%2520HIV-1-Infected%2520Macrophages%2520by%2520Targeted%2520Activator%2520of%2520Cell%2520Kill "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765927v1%26t%3DSelective%2520Elimination%2520of%2520HIV-1-Infected%2520Macrophages%2520by%2520Targeted%2520Activator%2520of%2520Cell%2520Kill "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765927v1%26title%3DSelective%2520Elimination%2520of%2520HIV-1-Infected%2520Macrophages%2520by%2520Targeted%2520Activator%2520of%2520Cell%2520Kill%26summary%3D%26source%3DbioRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.biorxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.11.11.765927v1%26title%3DSelective%2520Elimination%2520of%2520HIV-1-Infected%2520Macrophages%2520by%2520Targeted%2520Activator%2520of%2520Cell%2520Kill "Share on Mendeley") [ Citation Tools](https://www.biorxiv.org/ "Citation Tools") [ Get QR code](https://connect.biorxiv.org/qr/2026.11.11.765927) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.biorxiv.org/content/10.64898/2026.11.11.765927v1&count=horizontal&via=&text=Selective%20Elimination%20of%20HIV-1-Infected%20Macrophages%20by%20Targeted%20Activator%20of%20Cell%20Kill&counturl=www.biorxiv.org/content/10.64898/2026.11.11.765927v1 "Tweet This") ## Subject Area * [Immunology ](https://www.biorxiv.org/collection/immunology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.biorxiv.org/content/early/recent) * [Animal Behavior and Cognition](https://www.biorxiv.org/collection/animal-behavior-and-cognition) (8164) * [Biochemistry](https://www.biorxiv.org/collection/biochemistry) (19027) * [Bioengineering](https://www.biorxiv.org/collection/bioengineering) (15171) * [Bioinformatics](https://www.biorxiv.org/collection/bioinformatics) (45979) * [Biophysics](https://www.biorxiv.org/collection/biophysics) (22958) * [Cancer Biology](https://www.biorxiv.org/collection/cancer-biology) (20299) * [Cell Biology](https://www.biorxiv.org/collection/cell-biology) (27563) * [Clinical Trials](https://www.biorxiv.org/collection/clinical-trials) (138) * [Developmental Biology](https://www.biorxiv.org/collection/developmental-biology) (14275) * [Ecology](https://www.biorxiv.org/collection/ecology) (21590) * [Epidemiology](https://www.biorxiv.org/collection/epidemiology) (2067) * [Evolutionary Biology](https://www.biorxiv.org/collection/evolutionary-biology) (25993) * [G
## Related Clinical Research

- [Innate immune states linked to different serological responses after syphilis treatment](https://medichelpline.com/clinical-feed/biorxiv-3-distinct-innate-immune-states-associate-with-divergent-serological-outcomes.md)
- [mRNA Vaccination Induces HIV bnAb Precursor Maturation in Nonhuman Primates — Preprint Report](https://medichelpline.com/clinical-feed/biorxiv-5-hiv-broadly-neutralizing-antibody-precursor-maturation-induced-by-mrna.md)
- [Stakeholder preferences for long-acting injectables in tuberculosis treatment and prevention](https://medichelpline.com/clinical-feed/medrxiv-7-stakeholder-perspectives-and-preferences-for-long-acting-injectables-for.md)
- [Why some people have stronger vaccine side effects: immune signaling and what to do](https://medichelpline.com/clinical-feed/medical-news-today-0-vaccines-why-some-of-us-are-more-likely-to-experience-side-effects-and-what-to.md)
- [COVID-19 and Reactivation of Epstein-Barr, Herpes, and Anelloviridae: Study Findings](https://medichelpline.com/clinical-feed/medical-news-today-0-covid-19-may-reactivate-epstein-barr-herpes-viruses-what-this-means.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.